Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.
复制标题
DOI：
10.1097/ppo.0000000000000006
复制
发表时间：
2013-11
期刊：
影响因子：
--
通讯作者：
Yan J
中科院分区：
文献类型：
--
作者：
Albeituni SH;Ding C;Yan J
髓系细胞来源的抑制细胞(MDSC)是一组不成熟的髓系细胞，具有抑制特性，在癌症中优先扩张。MDSC主要抑制T细胞的增殖和细胞毒作用，抑制NK细胞的激活，诱导调节性T细胞(Tregs)的分化和扩增。MDSC在癌症中的广泛抑制活性及其在肿瘤进展中的作用使这些细胞成为有效的癌症免疫治疗的有希望的靶点。在这篇综述中，我们简要讨论了MDSC的起源及其主要的抑制机制，并重点介绍了迄今为止在荷瘤动物和癌症患者中靶向MDSC的方法。
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells with suppressive properties that preferentially expand in cancer. MDSC mainly suppress T cell proliferation and cytotoxicity, inhibit NK cell activation, and induce the differentiation and expansion of regulatory T cells (Tregs). The wide spectrum of MDSC suppressive activity in cancer and its role in tumor progression have rendered these cells a promising target for effective cancer immunotherapy. In this review we briefly discuss the origin of MDSC and their main mechanisms of suppression and focus more on the approaches developed up to date targeting of MDSC in tumor-bearing animals and cancer patients.